Testing a new medicine for hard-to-treat blood cancers

Plain-English translation of NCT06950034 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a Phase 1 clinical trial testing a new medication called for people with two types of advanced blood cancer—chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)—that have not responded to standard treatments. Researchers are studying whether this medication is safe and whether it can help control these cancers. You would receive the medication as an intravenous infusion (IV) every 3 weeks.

Current treatments don't work well enough for many people with these advanced blood cancers, especially when the disease has become resistant to standard chemotherapy. This trial exists to determine if this new treatment could offer hope for patients who have limited options.

Do you qualify?

You likely qualify if…

you have been diagnosed with chronic myelomonocytic leukemia (CMML) that has not responded to at least 4 cycles of standard treatment, or you discontinued treatment early due to side effects or worsening disease
you have been diagnosed with acute myeloid leukemia (AML) of a monocytic type that has come back or stopped responding to previous treatments
you are well enough to complete at least two treatment cycles, with a life expectancy of more than 2 months
you have adequate organ function (your heart, lungs, liver, and kidneys are working well enough)
you are willing to use contraception during the study and for 3 months after your last treatment dose

You likely don't qualify if…

you have acute promyelocytic leukemia (a specific type of AML) or leukemia that exists only outside the bone marrow
you are eligible for and able to have an immediate bone marrow transplant, which is a more established treatment option
you currently use any nicotine products, including tobacco, nicotine patches, or vaping
you have an active autoimmune condition that requires ongoing immunosuppressive treatment
you received chemotherapy, radiation, or other cancer treatments within the past 2 weeks

What participation looks like

You would receive infusions of the medication through an IV every 21 days (3 weeks). The trial has two stages: first, researchers will test increasing doses to find the safest dose, then expand to enroll more patients at the dose that works best. You would stay on treatment as long as the medication is helping and you are tolerating it well, with regular medical visits and blood tests to monitor your response and any side effects.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(7 sites)

United States

Stanford University, Stanford, California

Moffitt, Tampa, Florida

DFCI, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

OHSU, Portland, Oregon